Europe’s drug advisory committee recommended approval of Sanofi’s (SNY) oral MS therapy Cenrifki on April 24, a positive opinion that partially offsets a U.S. rejection and puts the company’s $3.7 billion Principia Biopharma acquisition closer to generating returns.
Investors watching Sanofi’s neurology pipeline should note that a formal European Commission decision – expected within months – would give Cenrifki its first major market authorization, helping the company recover value from a deal that has already generated a nearly €1.7 billion ($2 billion) impairment charge tied to setbacks in other MS indications.1
Key Takeaways
- EU advisory body backs Cenrifki for non-relapsing secondary progressive MS.
- FDA rejected the same drug in January over liver-injury safety concerns.
- HERCULES trial showed 31% reduction in disability progression vs. placebo.
Market Context & Competitive Positioning
The positive Committee for Medicinal Products for Human Use (CHMP) opinion positions Cenrifki (tolebrutinib) as potentially the first therapy specifically approved in Europe for secondary progressive MS (SPMS) patients who have not relapsed in the prior two years – a segment with few existing treatment options.2 Sanofi’s BTK inhibitor class faces competitive pressure from Roche, which is advancing its own brain-penetrant BTK blocker fenebrutinib for relapsing MS, though analysts have flagged lingering questions around that compound’s approval prospects.3
Among approved BTK inhibitors more broadly, Novartis secured FDA clearance for remibrutinib (Rhapsido) in chronic spontaneous urticaria in September 2025, and Sanofi itself holds an approved BTK inhibitor, Wayrilz, in a separate immune indication – underscoring the class’s commercial potential even as individual MS programs stumble.3
Detailed Analysis: The HERCULES Data and the Regulatory Split
The CHMP recommendation rests principally on the Phase 3 HERCULES study (NCT04411641), in which tolebrutinib delayed the onset of six-month confirmed disability progression by 31% versus placebo, and cut the adjusted mean number of new or enlarging T2 brain lesions by 38% per year.1 The EMA acknowledged drug-induced liver injury (DILI) as an identified risk but concluded the benefit-risk balance was favorable, subject to strict liver-monitoring requirements.3
That assessment diverges sharply from the FDA’s January 2026 rejection letter, which questioned the therapy’s net benefit and flagged the risk of severe or potentially fatal liver injury.2 Sanofi said the FDA’s decision represented a “significant and meaningful change in direction” from prior agency feedback, a characterization that left investors uncertain about any U.S. re-submission path.2
The impairment charge stemmed partly from a Phase 3 failure in primary progressive MS – the PERSEUS study missed its primary endpoint – which forced Sanofi to abandon planned regulatory filings in that subtype entirely.3 That leaves non-relapsing SPMS as the sole approved indication if the European Commission acts as expected.
Outlook & Management Commentary
Sanofi said disability progression “remains one of the most significant unmet needs in MS care,” framing the EU endorsement as validating its neurology strategy centered on smoldering neuroinflammation – the mechanism Cenrifki targets by penetrating the blood-brain barrier and inhibiting Bruton’s tyrosine kinase in resident immune cells.1 Additional regulatory reviews in other markets remain ongoing; the drug has already received provisional authorization in the United Arab Emirates for non-relapsing SPMS.3
For investors focused on M&A velocity and asset valuation, the EU recommendation provides a clearer commercial basis for the Principia Biopharma asset, acquired for $3.7 billion in 2020, than has existed at any point since the deal closed.2 However, the U.S. market remains closed absent a successful appeal or resubmission, which Sanofi has not publicly committed to pursuing.
Conclusion
The CHMP’s positive opinion is a meaningful but partial win for Sanofi: it secures a first regulatory foothold for Cenrifki and validates the HERCULES efficacy data, yet the transatlantic regulatory split introduces ongoing uncertainty about the drug’s global commercial ceiling. A final European Commission decision is anticipated within the coming months, at which point Sanofi’s neurology pipeline calculus – and the residual value of its Principia acquisition – will come into sharper focus for shareholders.
Not investment advice. For informational purposes only.
References
1Sanofi (April 24, 2026). “Press Release: Sanofi’s Cenrifki (tolebrutinib) recommended for EU approval by the CHMP to treat secondary progressive multiple sclerosis without relapses”. Sanofi. Retrieved June 23, 2026.
2Alvarado, Delilah (April 24, 2026). “Sanofi MS drug rejected in US gets an endorsement in Europe”. BioPharma Dive. Retrieved June 23, 2026.
3Dennis, Matthew (April 24, 2026). “Sanofi gets some good news for BTK inhibitor tolebrutinib, as EU body backs approval”. FirstWord Pharma. Retrieved June 23, 2026.
4(December 13, 2024). “Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis”. Sanofi. Retrieved June 23, 2026.